ABOS Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. (ABOS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $30.3K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Porter Derrell | Director | Sell | 13,040 | $2.33 | $30.3K | 35,500 −26.9% of holding | |
| Porter Derrell | Director | Sell | 12,800 | $2.33 | $29.8K | 35,500 −26.5% of holding | |
| Porter Derrell | Director | Sell | 6,460 | $2.35 | $15.1K | 48,300 −11.8% of holding | |
| Fountain Nathan B | Director | Sell | 6,400 | $2.23 | $14.3K | 48,150 −11.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.